date: 2022-06-24T08:17:34Z
pdf:unmappedUnicodeCharsPerPage: 0
pdf:PDFVersion: 1.7
pdf:docinfo:title: Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans
xmp:CreatorTool: LaTeX with hyperref
Keywords: antimicrobial peptides; invasive clinical isolates; combination therapy
access_permission:modify_annotations: true
access_permission:can_print_degraded: true
subject: In previous studies, derivatives of the peptide Pom-1, which was originally extracted from the freshwater mollusk Pomacea poeyana, showed an exceptional ability to specifically inhibit biofilm formation of the laboratory strain ATCC 90028 as a model strain of the pathogenic yeast Candida albicans. In follow-up, here, we demonstrate that the derivatives Pom-1A to Pom-1F are also active against biofilms of invasive clinical C. albicans isolates, including strains resistant against fluconazole and/or amphotericin B. However, efficacy varied strongly between the isolates, as indicated by large deviations in the experiments. This lack of robustness could be efficiently bypassed by using mixtures of all peptides. These mixed peptide preparations were active against biofilm formation of all the isolates with uniform efficacies, and the total peptide concentration could be halved compared to the original MIC of the individual peptides (2.5 g/mL). Moreover, mixing the individual peptides restored the antifungal effect of fluconazole against fluconazole-resistant isolates even at 50% of the standard therapeutic concentration. Without having elucidated the reason for these synergistic effects of the peptides yet, both the gain of efficacy and the considerable increase in efficiency by combining the peptides indicate that Pom-1 and its derivatives in suitable formulations may play an important role as new antibiofilm antimycotics in the fight against invasive clinical infections with (multi-) resistant C. albicans.
dc:creator: Michelle Häring, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker and Frank Rosenau
dcterms:created: 2022-06-24T07:43:31Z
Last-Modified: 2022-06-24T08:17:34Z
dcterms:modified: 2022-06-24T08:17:34Z
dc:format: application/pdf; version=1.7
title: Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans
Last-Save-Date: 2022-06-24T08:17:34Z
pdf:docinfo:creator_tool: LaTeX with hyperref
access_permission:fill_in_form: true
pdf:docinfo:keywords: antimicrobial peptides; invasive clinical isolates; combination therapy
pdf:docinfo:modified: 2022-06-24T08:17:34Z
meta:save-date: 2022-06-24T08:17:34Z
pdf:encrypted: false
dc:title: Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans
modified: 2022-06-24T08:17:34Z
cp:subject: In previous studies, derivatives of the peptide Pom-1, which was originally extracted from the freshwater mollusk Pomacea poeyana, showed an exceptional ability to specifically inhibit biofilm formation of the laboratory strain ATCC 90028 as a model strain of the pathogenic yeast Candida albicans. In follow-up, here, we demonstrate that the derivatives Pom-1A to Pom-1F are also active against biofilms of invasive clinical C. albicans isolates, including strains resistant against fluconazole and/or amphotericin B. However, efficacy varied strongly between the isolates, as indicated by large deviations in the experiments. This lack of robustness could be efficiently bypassed by using mixtures of all peptides. These mixed peptide preparations were active against biofilm formation of all the isolates with uniform efficacies, and the total peptide concentration could be halved compared to the original MIC of the individual peptides (2.5 g/mL). Moreover, mixing the individual peptides restored the antifungal effect of fluconazole against fluconazole-resistant isolates even at 50% of the standard therapeutic concentration. Without having elucidated the reason for these synergistic effects of the peptides yet, both the gain of efficacy and the considerable increase in efficiency by combining the peptides indicate that Pom-1 and its derivatives in suitable formulations may play an important role as new antibiofilm antimycotics in the fight against invasive clinical infections with (multi-) resistant C. albicans.
pdf:docinfo:subject: In previous studies, derivatives of the peptide Pom-1, which was originally extracted from the freshwater mollusk Pomacea poeyana, showed an exceptional ability to specifically inhibit biofilm formation of the laboratory strain ATCC 90028 as a model strain of the pathogenic yeast Candida albicans. In follow-up, here, we demonstrate that the derivatives Pom-1A to Pom-1F are also active against biofilms of invasive clinical C. albicans isolates, including strains resistant against fluconazole and/or amphotericin B. However, efficacy varied strongly between the isolates, as indicated by large deviations in the experiments. This lack of robustness could be efficiently bypassed by using mixtures of all peptides. These mixed peptide preparations were active against biofilm formation of all the isolates with uniform efficacies, and the total peptide concentration could be halved compared to the original MIC of the individual peptides (2.5 g/mL). Moreover, mixing the individual peptides restored the antifungal effect of fluconazole against fluconazole-resistant isolates even at 50% of the standard therapeutic concentration. Without having elucidated the reason for these synergistic effects of the peptides yet, both the gain of efficacy and the considerable increase in efficiency by combining the peptides indicate that Pom-1 and its derivatives in suitable formulations may play an important role as new antibiofilm antimycotics in the fight against invasive clinical infections with (multi-) resistant C. albicans.
Content-Type: application/pdf
pdf:docinfo:creator: Michelle Häring, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker and Frank Rosenau
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator: Michelle Häring, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker and Frank Rosenau
meta:author: Michelle Häring, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker and Frank Rosenau
dc:subject: antimicrobial peptides; invasive clinical isolates; combination therapy
meta:creation-date: 2022-06-24T07:43:31Z
created: 2022-06-24T07:43:31Z
access_permission:extract_for_accessibility: true
access_permission:assemble_document: true
xmpTPg:NPages: 17
Creation-Date: 2022-06-24T07:43:31Z
pdf:charsPerPage: 4043
access_permission:extract_content: true
access_permission:can_print: true
meta:keyword: antimicrobial peptides; invasive clinical isolates; combination therapy
Author: Michelle Häring, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker and Frank Rosenau
producer: pdfTeX-1.40.21
access_permission:can_modify: true
pdf:docinfo:producer: pdfTeX-1.40.21
pdf:docinfo:created: 2022-06-24T07:43:31Z